S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC

Abstract

non-adherence in 23/63 (36.5 %) and good adherence in 29/63 (46%). Agreement between clinician assessment and prescription issue data were seen in only 23/63 (36.5%) of cases and overall agreement using a weighted k coefficient was poor (weighted agreement 63.5%, expected agreement 58.8%, k 0.11, SE 0.1, z¼1.16, p¼0.12). There was no relationship between patients' age, gender, Juniper asthma control score, prescribed inhaled corticosteroid dose or FEV 1 percent predicted and the chances of agreement or disagreement between the two methods. Conclusions Clinical judgement alone appears to be a poor predictor of adherence to medication in patients with difficult asthma. The assessment of non-adherence requires objective measurements. Prescription issue data are one such measurement; but further work is required.

Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data

“…We were not able to identify the actual dose of neither cisplatin nor carboplatin and relied only on whether the agent was used or not during the first cycle of chemotherapy. An optimal dose of both cisplatin and carboplatin is known to affect outcomes 28 , we are not able to establish the dose used to treat our patients and thus is possible that an optimal dose of cisplatin was not used in our patients limiting our conclusions.…”

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

“…Of these, 12 RCTs were included, which involved a total of 4,139 patients ( Fig. 1) [14][15][16][17][18][19][20][21][22][23][24][25]. Relative to the previous Cochrane meta-analysis upon which the current review was based, two new RCTs were added, and updated results were captured from a third RCT [24][25][26].…”

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

“…It is noted that the results of recent meta-analyses44 45 suggest that cisplatin delivers greater efficacy than carboplatin, and that subsequently use of cisplatin has increased; however, clinical advice from experts confirms that clinical practice in the UK is still split between the two drugs. The results of the BTOG2 trial46 will help to clarify the evidence regarding the relative efficacy of cisplatin and carboplatin in terms of survival, QoL and the costs associated with each drug and its delivery.…”